Loading
A phase 1/2 trial of 9MW2921 in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., active and no longer recruiting.
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors. ClinicalTrials.gov record last updated 2024-11-21: active not recruiting. Enrollment is planned at 261 participants. Primary completion is estimated at 2026-09-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: 9MW2921. Registered primary measures: Dose Limited Toxicity (DLT); Adverse Events and Serious Adverse Events; ORR.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/